FDG-PET in the diagnosis of primary progressive aphasia: a systematic review
Annals of Nuclear Medicine · 2024-09 · 38 (9) · 673-687
DOI: 10.1007/s12149-024-01958-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Nuclear Medicine, online erschienen am 19.07.2024. Verfasst von Melika Mirbod und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Aphasia, Primary Progressive, Fluorodeoxyglucose F18, Positron-Emission Tomography. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, University of Oslo.
Abstract (Originalsprache)
Primary progressive aphasia (PPA) is a disease known to affect the frontal and temporal regions of the left hemisphere. PPA is often an indication of future development of dementia, specifically semantic dementia (SD) for frontotemporal dementia (FTD) and logopenic progressive aphasia (LPA) as an atypical presentation of Alzheimer’s disease (AD). The purpose of this review is to clarify the value of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-positron emission tomography (PET) in the detection and diagnosis of PPA. A comprehensive review of literature was conducted using Web of Science, PubMed, and Google Scholar. The three PPA subtypes show distinct regions of hypometabolism in FDG-PET imaging with SD in the anterior temporal lobes, LPA in the left temporo-parietal junction, and nonfluent/agrammatic Variant PPA (nfvPPA) in the left inferior frontal gyrus and insula. Despite the distinct patterns, overlapping hypometabolic areas can complicate differential diagnosis, especially in patients with SD who are frequently diagnosed with AD. Integration with other diagnostic tools could refine the diagnostic process and lead to improved patient outcomes. Future research should focus on validating these findings in larger populations and exploring the therapeutic implications of early, accurate PPA diagnosis with more targeted therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Epidemiology, Harvard Chan School of Public Health, Boston, MA, USA.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
- The Intervention Center, Division of Technology and Innovation, Oslo University Hospital, Oslo, Norway. m.e.rootwelt-revheim@medisin.uio.no.
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. m.e.rootwelt-revheim@medisin.uio.no.
Förderung
- NIGMS NIH HHS
- University of Oslo
Zitieren
APA
Mirbod, M., Ayubcha, C., Redden, H. W. K., Teichner, E., Subtirelu, R. C., Patel, R., Raynor, W., Werner, T., Alavi, A., & Revheim, M. E. (2024). FDG-PET in the diagnosis of primary progressive aphasia: a systematic review. Annals of Nuclear Medicine, 38(9), 673-687. https://doi.org/10.1007/s12149-024-01958-w
Vancouver
Mirbod M, Ayubcha C, Redden HWK, Teichner E, Subtirelu RC, Patel R, et al. FDG-PET in the diagnosis of primary progressive aphasia: a systematic review. Annals of Nuclear Medicine. 2024;38(9):673-687. doi:10.1007/s12149-024-01958-w
BibTeX
@article{Mirbod2024,
author = {Mirbod, Melika and Ayubcha, Cyrus and Redden, Hyae Won Kim and Teichner, Eric and Subtirelu, Robert C and Patel, Raj and Raynor, William and Werner, Thomas and Alavi, Abass and Revheim, Mona-Elisabeth},
title = {FDG-PET in the diagnosis of primary progressive aphasia: a systematic review},
journal = {Annals of Nuclear Medicine},
year = {2024},
volume = {38},
number = {9},
pages = {673--687},
doi = {10.1007/s12149-024-01958-w}
}
EUVIMED